Your browser doesn't support javascript.
loading
Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and ß-synuclein in human cerebrospinal fluid.
Na, Chan Hyun; Sathe, Gajanan; Rosenthal, Liana S; Moghekar, Abhay R; Dawson, Valina L; Dawson, Ted M; Pandey, Akhilesh.
Afiliação
  • Na CH; 1Neurodegeneration Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
  • Sathe G; 2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
  • Rosenthal LS; Diana Helis Henry Medical Research Foundation, New Orleans, LA 70130 USA.
  • Moghekar AR; Diana Helis Henry Medical Research Foundation, New Orleans, LA 70130 USA.
  • Dawson VL; 9Present Address: Center for Molecular Medicine, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, 560 029 India.
  • Dawson TM; 2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
  • Pandey A; 2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA.
Clin Proteomics ; 17: 13, 2020.
Article em En | MEDLINE | ID: mdl-32390785
ABSTRACT

BACKGROUND:

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder. Biomarkers that can help monitor the progression of PD or response to disease-modifying agents will be invaluable in making appropriate therapeutic decisions. Further, biomarkers that could be used to distinguish PD from other related disorders with PD-like symptoms will be useful for accurate diagnosis and treatment. C-Abl tyrosine kinase is activated in PD resulting in increased phosphorylation of the tyrosine residue at position 39 (Y39) of α-synuclein (α-syn) (pY39 α-syn), which contributes to the death of dopaminergic neurons. Because pY39 α-syn may be pathogenic, monitoring pY39 α-syn could allow us to diagnose presymptomatic PD and help monitor disease progression and response to treatment. We sought to investigate if increased phosphorylation of pY39 α-syn can be detected in the cerebrospinal fluid (CSF) of PD patients by targeted mass spectrometry.

METHODS:

Here, we report a two-step enrichment method in which phosphotyrosine peptides were first enriched with an anti-phosphotyrosine antibody followed by a second round of enrichment by titanium dioxide (TiO2) beads to detect EGVLpYVGSK sequence derived from tyrosine 39 region of α- and ß-synuclein (αß-syn). Accurate quantification was achieved by adding a synthetic heavy version of pY39 αß-syn peptide before enzymatic digestion.

RESULTS:

Using the developed enrichment methods and optimized parallel reaction monitoring (PRM) assays, we detected pY39 αß-syn peptide in human CSF and demonstrated that the ratio of pY39 αß-syn to Y39 αß-syn was significantly increased in the CSF of patients with PD.

CONCLUSIONS:

We anticipate that this optimized two-step enrichment-based PRM detection method will help monitor c-Abl activation in PD patients and can also be used to quantify other phosphotyrosine peptides of low abundance in biological samples.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article